Patents by Inventor Emma Joanne Carlson

Emma Joanne Carlson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent for treatment of depression or anxiety
    Patent number: 6649614
    Abstract: The present invention relates to the treatment of depression and/or anxiety by the administration of a combination of a specific class of NK-1 receptor antagonists and an antidepressant or anti-anxiety agent.
    Type: Grant
    Filed: October 16, 2001
    Date of Patent: November 18, 2003
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Emma Joanne Carlson, Nadia Melanie Rupniak
  • Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
    Publication number: 20020042361
    Abstract: The present invention relates to the treatment or prevention of depression and/or anxiety by the administration of a combination of a specific class of NK-1 receptor antagonists and an antidepressant or anti-anxiety agent. The present invention also provides preclinical screens for anxiolytic and antidepressant activity of NK-1 receptor antagonists.
    Type: Application
    Filed: October 16, 2001
    Publication date: April 11, 2002
    Applicant: Merck Sharp & Dohme Ltd.
    Inventors: Emma Joanne Carlson, Nadia Melanie Rupniak
  • Treatment of depression and anxiety with fluoxetine and an NK-1 receptor antagonist
    Patent number: 6319953
    Abstract: The present invention relates to the treatment or prevention of depression and/or anxiety by the administration of a combination of a specific class of NK-1 receptor antagonists and fluoxetine.
    Type: Grant
    Filed: December 8, 1999
    Date of Patent: November 20, 2001
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Emma Joanne Carlson, Nadia Melanie Rupniak
  • Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
    Patent number: 6117855
    Abstract: The present invention relates to the treatment or prevention of depression and/or anxiety by the administration of a combination of CNS-penetrant NK-1 receptor antagonists and an antidepressant or anti-anxiety agent.
    Type: Grant
    Filed: December 19, 1997
    Date of Patent: September 12, 2000
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Emma Joanne Carlson, Nadia Melanie Rupniak